Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alobresib Monotherapy and Combination in Advanced Tumors
NCT02392611Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2015
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of alobresib in solid tumor, lymphoma and breast cancer (9 arms), sponsored by Gilead Sciences. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Mar 2015; status: completed.
02
Drugs
alobresib
03
Conditions
solid tumorlymphomabreast cancer
Beyond the preview
Go deeper on NCT02392611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02392611.